Merck Completes Acquisition of EyeBio

By Staff
Monday, July 15, 2024 12:18 AM RAHWAY, N.J.—Merck, a research-intensive biopharmaceutical company known as MSD outside of the U.S. and Canada, has announced the completion of the acquisition of Eyebiotech Limited, a privately held ophthalmology-focused biotechnology company.

NovaBay Pharmaceuticals Reports Preliminary Second Quarter 2024 Net Revenue of $2.4 Million

By Staff
Friday, July 12, 2024 12:24 AM EMERYVILLE, Calif.—NovaBay Pharmaceuticals, Inc. (NYSE American: NBY), a developer of eyecare, skin care and wound care products, has announced preliminary net revenue of $2.4 million for the second quarter of 2024 and $5.0 million for the first half of 2024, primarily derived from the company’s eyecare products. Net revenue from the company’s eyecare products increased by 9 percent for both the second quarter and the first half of 2024 compared with the corresponding periods in 2023, the company noted. NovaBay also said it expects 2024 net revenue from the company’s eyecare products to be approximately $10 million.

KITS Eyecare Preliminary Q2 Financial Results Show 25 Percent Year-Over-Year Growth

By Staff
Friday, July 5, 2024 12:24 AM VANCOUVER, British Columbia—KITS Eyecare Ltd. (TSX: KITS), a vertically integrated eyecare provider, has provided selected preliminary unaudited results for the second quarter ended June 30, 2024. According to the company, total revenue grew 25 percent year-over-year to approximately $37.5 million. The company also reported that adjusted EBITDA increased year-over-year to over 3 percent of revenue and that it finished the second quarter with a cash balance of more than $19.0 million.

Beacon Therapeutics Raises $170 Million in Series B Funding to Advance Development of Ophthalmic Gene Therapies, Adds to Board of Directors

By Staff
Friday, July 5, 2024 12:21 AM LONDON and CAMBRIDGE, Mass.—Beacon Therapeutics Holdings Limited, an ophthalmic gene therapy company that works to save and restore the vision of patients with blinding retinal diseases, has announced it has raised $170 million in Series B funding to advance the development of ophthalmic gene therapies.

Glaukos Announces Agreements to Exchange $230 Million in Principal Amount of Its 2.75 Percent Convertible Senior Notes Due 2027 for Common Stock

By Staff
Monday, June 17, 2024 12:21 AM ALISO VIEJO, Calif.—Glaukos Corporation, an ophthalmic pharmaceutical and medical tech company, has announced that it entered into separate, privately negotiated exchange agreements with certain holders of its 2.75 percent convertible senior notes due 2027.

CooperCompanies Announces Q2 2024 Financial Results and Raises Full-Year Guidance

By Staff
Friday, May 31, 2024 12:30 AM CooperCompanies announces Q2 2024 financial results; KeraLink International names a new president and CEO; Merck to acquire EyeBio; CooperCompanies publishes 2023 ESG report; and The Vision Council releases new inSights research all topped this week’s VMAIL news feed. Click on the headlines below to catch up on anything you might have missed.

CooperCompanies Announces Q2 2024 Financial Results and Raises Full-Year Guidance

By Staff
Friday, May 31, 2024 12:27 AM SAN RAMON, Calif.—CooperCompanies (Nasdaq: COO), a global medical device company, has announced financial results for its fiscal second quarter ended April 30, 2024. CooperCompanies reported revenues under two major segments—CooperVision (CVI) and CooperSurgical (CSI). The company reported that overall revenue increased 7 percent year-over-year to $942.6 million. CVI revenue was up 8 percent to $635.9 million and CSI revenue grew 6 percent to $306.7 million, according to the announcement. "I'm pleased to report record quarterly revenues and great operational progress throughout the organization," said Al White, Cooper's president and CEO.

Merck to Acquire EyeBio for Up to $3 Billion

By Staff
Thursday, May 30, 2024 12:21 AM RAHWAY, N.J. and NEW YORK—Merck (NYSE: MRK), known as MSD outside of the U.S. and Canada, and Eyebiotech Limited (EyeBio), a privately held ophthalmology-focused biotechnology company, announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire EyeBio. Under the terms of the agreement, Merck will acquire all outstanding shares of EyeBio for up to $3 billion, including an upfront payment of $1.3 billion in cash and a further potential $1.7 billion in developmental, regulatory and commercial milestone payments, the announcement stated. The acquisition has been unanimously approved by the EyeBio board of directors.

Innovative Eyewear, Inc. Announces $2.5 Million Registered Direct Offering of Common Stock

By Staff
Thursday, May 30, 2024 12:18 AM MIAMI—Innovative Eyewear, Inc., a developer and seller of smart eyewear, has announced that it has entered into a definitive agreement for the issuance and sale of 5,263,161 shares of its common stock at a purchase price per share of $0.475 in a registered direct offering priced at-the-market under Nasdaq rules.

BJ’s Wholesale Club Holdings, Inc. Announces First Quarter Fiscal Results for 2024

By Staff
Friday, May 24, 2024 12:24 AM MARLBOROUGH, Mass.—BJ’s Wholesale Club Holdings, Inc. (NYSE: BJ) has announced its financial results for the thirteen weeks ended May 4, 2024. Total comparable club sales increased by 1.6 percent in the first quarter of fiscal 2024 compared with the first quarter of fiscal 2023.

Rodenstock Reports Year-End 2023 Financial Results

By Staff
Friday, May 24, 2024 12:21 AM MUNICH—Rodenstock Group, a global innovation leader in vision care and manufacturer of biometric lenses, has announced its results for the financial year 2023.

Eyeglass Lens Sales Help Drive Hoya's Growth for Q4 and Full-Year

By Staff
Wednesday, May 22, 2024 12:18 AM Editor's Note: A version of this article that appeared in VMAIL on May 16, 2024, incorrectly reported the monetary units. This version reflects corrected monetary units.

TOKYO—Hoya Corporation has announced consolidated revenue of 196.8 billion yen for the fourth quarter ending March 31, 2024, up 6 percent from year-ago.

De Rigo Group Reports Full-Year 2023 Financial Results

By Staff
Tuesday, May 21, 2024 12:24 AM LONGARONE, Italy—The De Rigo Group board of directors has approved the results for the year 2023 with a consolidated turnover of €506.1 million compared with €452.7 million in 2022, representing an increase of 11.8 percent. At constant exchange rates, the increase compared with 2022 was 16 percent, according to the company. Net sales in the Americas for 2023 grew by 5.1 percent to €57.5 million, compared with €54.7 million in 2022. At 2022 exchange rates, the net sales achieved in this region amounted to €58.8 million, the company said.

Walmart Reports Strong First Quarter Results, Reaffirms Commitment to Optical Business

By Staff
Friday, May 17, 2024 12:24 AM BENTONVILLE, Ark.—Walmart Inc. (NYSE: WMT) has announced first quarter financial results for the three months ending on April 30, 2024, showcasing strong growth in revenue and operating income. The results shared by the omnichannel, global retailer are for Q1 of its 2025 fiscal year, which runs for 12 months ending January 31, 2025. Specific highlights for the first quarter include consolidated revenue of $161.5 billion, up 6.0 percent, or 5.8 percent constant currency versus the same period last year; reported operating income up $0.6 billion (9.6 percent) and adjusted operating income up 13.7 percent, attributed to higher gross margins and growth in membership income; and growth in global e-commerce sales by 21 percent, led by store-fulfilled pickup/delivery and marketplace.

Zeiss Group Reports Double Digit Revenue Growth in First Half of Fiscal Year

By Staff
Friday, May 17, 2024 12:21 AM OBERKOCHEN, Germany—The Zeiss Group has reported the results of the first half of fiscal year 2023/24. The group generated revenue totaling €5.304 million for the period ended March 31, 2024.